Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists

BackgroundThe endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). This study quantified how clinicians weigh the...

詳細記述

書誌詳細

出版年:	Frontiers in Neurology
主要な著者:	Sebastian Heidenreich, Myrto Trapali, Nicolas Krucien, Andrea Phillips-Beyer
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-03-01
主題:	discrete choice experiment (DCE) aneurysmal subarachnoid hemorrhage delayed cerebral ischemia endothelin receptor antagonist (ERA) physician preference clinician preference
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1102290/full